دورية أكاديمية
أعرض في EDS

Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy.

التفاصيل البيبلوغرافية
العنوان: Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy.
المؤلفون: Bogart M; Customer Engagement, Value, Evidence and Outcomes (CEVEO) US Medical Affairs, GSK, Research Triangle Park, NC, USA., Leung GY; STATinMED Research, Dallas, TX, USA., Cyhaniuk A; STATinMED Research, Dallas, TX, USA., DiRocco K; US Medical Affairs, GSK, Collegeville, PA, USA.
المصدر: International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2024 Feb 13; Vol. 19, pp. 439-450. Date of Electronic Publication: 2024 Feb 13 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101273481 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2005 (Electronic) Linking ISSN: 11769106 NLM ISO Abbreviation: Int J Chron Obstruct Pulmon Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Auckland, N.Z. : DOVE Medical Press,
مواضيع طبية MeSH: Pulmonary Disease, Chronic Obstructive*/diagnosis , Pulmonary Disease, Chronic Obstructive*/drug therapy , Quinuclidines*, Humans ; Aged ; United States ; Tiotropium Bromide/adverse effects ; Bronchodilator Agents/adverse effects ; Inpatients ; Retrospective Studies ; Aftercare ; Treatment Outcome ; Forced Expiratory Volume ; Administration, Inhalation ; Patient Discharge ; Medicare ; Benzyl Alcohols/adverse effects ; Chlorobenzenes/pharmacology ; Drug Combinations
مستخلص: Purpose: Patients with chronic obstructive pulmonary disease (COPD) who are hospitalized are more likely to die from their illness and have increased likelihood of re-admission than those who are not. Subsequent re-admissions further increase the burden on healthcare systems. This study compared inpatient admission rates and time-to-first COPD-related inpatient admission among Medicare beneficiaries with COPD indexed on umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO).
Patients and Methods: This retrospective study used the All-Payer Claims Database to investigate hospital admission and re-admission outcomes in Medicare beneficiaries with COPD with an initial pharmacy claim for UMEC/VI or TIO from 1 January 2015 to 28 February 2020. Inpatient admissions, baseline, and follow-up variables were assessed in patients indexed on UMEC/VI and TIO after propensity score matching (PSM), with time-to-first on-treatment COPD-related inpatient admission as the primary endpoint. Re-admissions were assessed among patients with a COPD-related inpatient admission in the 30- and 90-days post-discharge.
Results: Post-PSM, 7152 patients indexed on UMEC/VI and 7069 on TIO were eligible for admissions analysis. The mean (standard deviation [SD]) time-to-first COPD-related inpatient admission was 46.71 (87.99) days for patients indexed on UMEC/VI and 44.96 (85.90) days for those on TIO (p=0.06). The mean (SD) number of inpatient admissions per patient was 1.24 (2.92) for patients indexed on UMEC/VI and 1.26 (3.05) for those on TIO (p=0.49). Proportion of patients undergoing re-admissions was similar between treatments over both 30 and 90 days, excluding a significantly lower proportion of patients indexed on UMEC/VI than those indexed on TIO for COPD-related re-admissions for hospital stays of 4-7 days and 7-14 days, and all-cause re-admissions for stays of 4-7 days.
Conclusion: Patients with COPD using Medicare in the US and receiving UMEC/VI or TIO reported similar time-to-first inpatient admission and similar proportion of re-admissions.
Competing Interests: MB and KD are employees of GSK and hold stock and shares at GSK or were employees and did hold stock and shares at the time of the study. GL and AC were employees of STATinMED Research at the time of the study, which received funding from GSK to conduct the study. STATinMED Research is a business that provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. STATinMED Research employees work with a variety of companies and organizations and are expressly prohibited from receiving any payment or honoraria directly from these organizations for services rendered.
(© 2024 Bogart et al.)
References: Lancet Respir Med. 2014 Jun;2(6):472-86. (PMID: 24835833)
BMC Pulm Med. 2021 Jul 31;21(1):253. (PMID: 34332555)
BMJ. 2022 Jul 27;378:e069679. (PMID: 35896191)
Adv Ther. 2022 Nov;39(11):4961-5010. (PMID: 35857184)
Respir Med. 2013 Oct;107(10):1538-46. (PMID: 23830094)
J Health Polit Policy Law. 2023 Feb 1;48(1):93-115. (PMID: 36112957)
Int J Chron Obstruct Pulmon Dis. 2022 Feb 10;17:329-342. (PMID: 35177901)
Am J Respir Crit Care Med. 2020 May 1;201(9):e56-e69. (PMID: 32283960)
PLoS One. 2020 May 11;15(5):e0233147. (PMID: 32392262)
Respir Med. 2014 Dec;108(12):1752-60. (PMID: 25458157)
MMWR Morb Mortal Wkly Rep. 2019 Jun 21;68(24):533-538. (PMID: 31220055)
Int J Chron Obstruct Pulmon Dis. 2017 Feb 24;12:745-755. (PMID: 28280319)
Ann Am Thorac Soc. 2018 Jul;15(7):837-845. (PMID: 29611719)
Thorax. 2009 Oct;64(10):863-8. (PMID: 19553233)
Int J Chron Obstruct Pulmon Dis. 2021 Apr 22;16:1149-1161. (PMID: 33911860)
Chronic Obstr Pulm Dis. 2016 Aug 29;3(4):729-738. (PMID: 28848899)
Pulm Ther. 2021 Jun;7(1):203-219. (PMID: 33728597)
فهرسة مساهمة: Keywords: COPD; hospital admissions; hospital re-admissions; initial maintenance therapy; tiotropium monotherapy; umeclidinium/vilanterol dual therapy
المشرفين على المادة: XX112XZP0J (Tiotropium Bromide)
028LZY775B (vilanterol)
0 (GSK573719)
0 (Bronchodilator Agents)
0 (Benzyl Alcohols)
0 (Chlorobenzenes)
0 (Drug Combinations)
0 (Quinuclidines)
تواريخ الأحداث: Date Created: 20240220 Date Completed: 20240221 Latest Revision: 20240221
رمز التحديث: 20240221
مُعرف محوري في PubMed: PMC10874883
DOI: 10.2147/COPD.S436654
PMID: 38374817
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-2005
DOI:10.2147/COPD.S436654